Oregon Health Plan and GLP-1s
Oregon organizes coverage around what the evidence supports rather than around what a drug is labeled for, and it publishes the resulting table. Liraglutide qualifies only for liver disease. Semaglutide qualifies for cardiovascular disease or liver disease. Tirzepatide qualifies for sleep apnea. Weight management alone qualifies for nothing — except that children keep a case-by-case review.
What changed, and what the document says
The note above the evidence table
Not coveredOregon states the rule as a heading over the table rather than burying it in a criteria step, so it governs everything below.
“Note: Drugs prescribed for only weight management (overweight or obesity) are NOT currently covered”
Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24
A table of what the evidence supports
ContextThe organizing idea is unusual: the list is of indications backed by evidence, not of drugs approved by a regulator.
“Table 3. Evidence-Supported Indications”
Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24
Children keep a case-by-case route
CoveredThe children's benefit is named as a goal of the policy itself, which is a different posture from an adult-only refusal.
“Allow case-by-case review for members covered under the EPSDT program.”
Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24
Tirzepatide's one indication
Conditions applyThe evidence table gives each drug its own row. Tirzepatide gets a single line, and it is about breathing.
“Moderate to severe obstructive sleep apnea (OSA) in adults with obesity”
Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24
The committee changed it in February
CoveredOregon's committee voted to drop a step-therapy requirement, which makes the liver-disease route shorter for people without diabetes.
“Recommendations: Remove Ozempic step through for Wegovy for patients who do not have diabetes”
Drug Use Research & Management Program, Oregon Health Authority Health Systems Division — Thursday, February 5th, 2026
It went through the committee as an agenda item
ContextThe change was presented, taken to public comment and voted, rather than issued as a bulletin.
“Motion to approve, 2nd, all in favor”
Drug Use Research & Management Program, Oregon Health Authority Health Systems Division — Thursday, February 5th, 2026
Which of these companies serve Oregon?
Of the 242 companies we grade, 25 publish a list of the states they are licensed in. We checked 214 more and found no such list on any page we read; 3 we have not checked either way.
19 of those lists name Oregon: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Invyncible, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.
A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.
Sources
Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.
- Weight Management Drugs — prior authorization criteria — Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division. The two histories the footer prints, labeled there as P and T / DUR Review and Implementation; the document prints no single effective date: Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24.
- Oregon Drug Use Review / Pharmacy & Therapeutics Committee — meeting minutes — Drug Use Research & Management Program, Oregon Health Authority Health Systems Division. Meeting date printed under the committee name on page 1: Thursday, February 5th, 2026.
Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.
If you're paying cash instead
None of the above changes what a telehealth seller charges you. None of the 3 rows below carries both a medication price and a monthly fee we could capture, so no figure here is a sum. Each cell says what its number covers and what we could not confirm, and every number was read on the seller's own page.
Zealthy, Noom Med and Signos pay us nothing — none of the 3 below does. The buttons run through our own redirect so we can count the click, and counting is all they do.
| Grade | Provider | What a month actually costs | The one thing that matters here | Go to the provider |
|---|---|---|---|---|
| CCaveat | Zealthy | $297a month, medication onlycompounded semaglutideMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.Advertised at $151The lowest of the 2 medication prices we captured here | Advertises $151 for compounded semaglutide and bills $297, with tirzepatide at $216 advertised against $449 billed — a gap worth seeing before comparing against a plan that covers neither for weight alone. | See its prices at Zealthy (opens in a new tab)Pays us nothing |
| CCaveat | Noom Med | $279a month, medication onlycompounded semaglutideMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.Advertised at $129The lowest of the 2 medication prices we captured here | Shows $129 and $149 in its advertising and $279 and $299 on the plan itself, which is the same advertised-versus-billed shape and the reason we print both numbers. | See its prices at Noom Med (opens in a new tab)Pays us nothing |
| CCaveat | Signos | $199a month, medication onlycompounded GLP-1 with CGMMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.The only figure published for this plan, and it is worded as a floor. | Sells a continuous glucose monitor program rather than a drug — $225 for one month, $127 a month over six — which is the kind of non-drug route a state that funds conditions rather than weight leaves open. | See its prices at Signos (opens in a new tab)Pays us nothing |
Our grading method and how we verify a price explain what those letters mean and where these figures came from.